CGON (CG Oncology) Other Long-Term Liabilities : $-0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Other Long-Term Liabilities?

CG Oncology's other long-term liabilities for the quarter that ended in Mar. 2025 was $-0.00 Mil.

CG Oncology's quarterly other long-term liabilities increased from Sep. 2024 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Mar. 2025 ($-0.00 Mil).

CG Oncology's annual other long-term liabilities declined from Dec. 2022 ($0.35 Mil) to Dec. 2023 ($0.01 Mil) and declined from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.00 Mil).

CG Oncology Other Long-Term Liabilities Historical Data

The historical data trend for CG Oncology's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Other Long-Term Liabilities Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

0.35

0.01

CG Oncology Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial						-	-	-	-	-

CG Oncology Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

CG Oncology Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of CG Oncology's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.